Drug Trial Radar · NCT06967259
ENA-001 for Opioid Induced Respiratory Depression
Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
62
Actual
Start
May 14, 2025
Primary completion
Aug 12, 2026
Study completion Aug 12, 2026
Sponsor
- Lead sponsor
- Enalare Therapeutics Inc.Industry
- Sponsor type
- Industry
- Collaborators
- National Institute on Drug Abuse (NIDA)
- First posted
- May 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a Phase I clinical trial to assess the safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) profiles with single intravenous (IV) and intramuscular (IM) doses of ENA-001.
Conditions
- Respiratory Depression
Interventions
ENA-001Drug
Concentration for ENA-001 IV formulation is 10 mg/mL. Concentration for ENA 001 IM formulation is 30 mg/mL.
Placebo ComparatorDrug
Placebo comes in 5 mL/vial. Placebo matches ENA-001 injection; however, no ENA-001 is included.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Range values of laboratory tests (Safety)Time frame: From screening to follow up visit (approx. 8 weeks)
- Range values of special chemistry tests (Safety)Time frame: From screening to follow up visit (approx. 8 weeks)
- Vital Sign measurements (Safety and tolerability)Time frame: From screening to follow up visit (approx. 8 weeks)
- Measurement of ECG parameters (Safety and tolerability)Time frame: From screening to follow up visit (approx. 8 weeks)
- Complete Physical Exam Findings (Safety and tolerability)Time frame: From screening to follow up visit (approx. 8 weeks)
- Incidence of Adverse Events (Safety and tolerability)Time frame: From screening to follow up visit (approx. 8 weeks)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
South Florida Research Phase I-IV
Miami, Florida
Dr. Vince Clinical Research
Overland Park, Kansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.